Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life by Ditto, Maria Chiara et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Rheumatic Diseases and 
Biosimilars: Evidence about Switch 
from Originators to Biosimilars in 
the Real Life
Maria Chiara Ditto, Simone Parisi, Rossella Talotta, 
Marta Priora, Richard Borrelli and Enrico Fusaro
Abstract
Biosimilars are broadly available for the treatment of several diseases  
including inflammatory arthritis. Thanks to biosimilars it has been possible to treat 
a greater number of rheumatic patients who previously were undertreated due to 
the high cost of originators, in several countries. There are a lot of data from double 
blind, randomized, controlled clinical trials, especially on TNF inhibitors (TNFi), 
concerning the maintenance of clinical efficacy after switching from originators 
to biosimilars; therefore, such a transition is increasingly encouraged both in the 
US and Europe mainly for economic reasons. However, despite the considerable 
saving, such shifts to biosimilar drugs are still being debated, principally over 
their ethical implications. Since the drugs are similar but not identical, the main 
issues are related to the possibility to compare the adverse events and/or the lack of 
efficacy and, to date, the variability in effectiveness for a single patient remains an 
unpredictable datum before effecting the switch. Despite encouraging data about 
the maintenance of efficacy and safety after the switch, there are many reports of 
discontinuation due both lack of efficacy or and adverse events. In this chapter we 
aim at showing the disease activity trend and the safety after the transition to TNF-i 
biosimilars in patients with rheumatic diseases in real life..
Keywords: Infliximab, Etanercept, Adalimumab, real-life, originator, biosimilar, 
switch
1. Introduction
As previously stated, a biosimilar is a biological product that is highly similar to 
and has no clinically meaningful differences from an existing approved reference 
product (RF). Before they are approved, biosimilars are requested to undergo a 
precise development process in order to establish biosimilarity when compared to 
their originator. The European Medicines Agency’s (EMA) Scientific Committees 
evaluate biosimilars according to the same standards that apply to all biological 
medicines; in fact, every new biosimilar is required to produce studies that show 
to what extent it is similar to the RF originator and that there are no clinically 
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meaningful differences between them in terms of safety, quality and efficacy. This 
element allows avoiding the repetition of clinical trials already carried out with the 
originator in the first place; in fact, rule no. EMA/CHMP/BWP/3354/1999 clearly 
states that “(…) biologic drugs are required to undergo proper studies for each reg-
istration and disease of pertinence” [1]. In order to get the approval, each biosimilar 
must give a coherent justification as to why the indication in question makes use of 
extrapolation instead of carrying out a comparative study in each case [2]; in this 
context, the extrapolation allows the indication of a biosimilar to be transferred 
to another indication where only the originator was tested without performing 
additional clinical studies with the biosimilar in the other indication due to their 
aforementioned similarity which is given by the definition itself. However, there are 
concerns that these differences may impact on efficacy or safety in certain indica-
tions, which extrapolations cannot establish properly.
Nevertheless, given the efforts inferred by the development and the analysis of the 
studies requested to approve the originators, biosimilars can only be authorized once 
the period of data exclusivity on the ‘reference’ biological medicine has expired; in 
general, this timelasts for at least eight years from the marketing authorization [3].
Despite the approval given by the European League Against Rheumatism 
(EULAR) to insert the possibility to use biosimilars in the guide lines, it is quite 
manifest that, to date, both a certain struggle and a severe mistrust in the usage 
of such biosimilars are still very present among clinicians and patients [4]. 
These problems origin from various concerns; one of the main complications in 
the usage of biosimilars comes from double-blind randomized controlled trials 
(RCTs) concerning the maintenance of clinical efficacy after switching from 
originators. To date, many studies have been showing conflicting results on the 
topic, which has led physicians to mistrust the clinical effectiveness of the switch 
for patients in therapy with originators [5]. Contrariwise, more and more studies 
and societies are gathering data confirming that comparable efficacy and toler-
ability were observed in patients who switched since data support the long-term 
efficacy of biosimilars in patients with rheumatic diseases [6]. In fact, in the 
majority of studies, efficacy endpoints were maintained in the switch group as 
well as the number of patients with remission as per ACR/EULAR criteria.
One of the most important studies, NOR-SWITCH, was published in 2017 on 
Lancet; its main purposes were to evaluate the switch from originator infliximab 
(IFX) to biosimilar CT-P13 and to compare its effectiveness with the maintained 
treatment with IFX. In order to achieve this goal, a 52-week, randomized, double-
blind, non-inferiority trial was performed gathering data from 40 Norwegian study 
centres. Only patients on stable treatment with the originator for at least 6 months 
before randomization were included. Two hundred and fourty one out of 481 
patients were on continued treatment and 240 were switched from the originator to 
CT-P13. The frequency of adverse events was similar between groups, and switch-
ing was not shown to affect clinical endpoints. The results of this study strongly 
revealed that switching from the originator to the biosimilar TNF-i does not result 
in worse outcomes than continued therapy with the originator with the assumed 
non-inferiority margin of 15%. Similar results were obtained from other important 
studies in patients with Rheumatoid Arthritis such as PLANETRA (71.8% and 
71.8%, respectively, for ACR20, 48% and 51.4%, respectively, for ACR50, and 
24.3% and 26.1%, respectively, for ACR70) as well as from registries like DANBIO; 
these two elements predominantly focused on IFX.
Another valuable aspect has to be considered whilst discussing the shift to bio-
similars: Health technology assessment (or HTA). The rationale for a biosimilar is to 
promote competition among manufacturers to lower prices and potentially increase 
access to affordable therapies.
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A Canadian study concerning biosimilars and their impact on health-related 
budget showed that in a two-year period of time, approximately one billion dollars 
in savings could have been realized through exclusive purchasing of biosimilar 
drugs for IFX, filgrastim, and insulin glargine as opposed to the originator products 
[7]. However, to date, in the US this phenomenon is not as frequent as it appears 
to be in Europe since a report compiled in 2018 indicated that only 3% of biologic 
spending (which is equivalent to US$3.2 billion)is subject to competition from 
biosimilar products [8].
Nonetheless, despite the considerable saving, such shifts to biosimilar drugs are 
still being debated, principally over their ethical implications. Since the drugs are 
similar but not identical, the main issues are related to the possibility to compare 
the adverse events and/or the lack of efficacy and, to date, the variability in effec-
tiveness for a single patient remains an unpredictable datum before effecting the 
switch. Despite data about the maintenance of efficacy and safety after the switch, 
there are many reports of discontinuation in real life data due both lack of efficacy 
or adverse events.
The European Medicines Agency (EMA) was the first regulatory body to develop 
a specific regulatory pathway for the approval of biosimilars when it published 
‘Guidelines on similar biological medicinal products’ in 2005 [9]. Since then, many 
biosimilar agents have been approved by regulatory agencies in Europe and North 
America. The first biosimilars were the somatropin analogs, introduced in Europe. 
Erythropoietin biosimilars followed in 2007.
The TNF-i biosimilars approved in Rheumatology are biosimilars of 3 molecules, 
IFX, ETA and Adalimumab (ADA).
2. Immunogenicity
Immunogenicity is by definition the property of a substance to induce an immune 
response usually mediated by the adaptive immune system [10]. When applied to the 
pharmacological field, immunogenicity may represent both a desired (e.g., with the 
use of vaccines) or undesired (e.g., during a treatment with biological agents) event. 
Big molecules, like monoclonal antibodies (moAbs) or their derivates are high induc-
tors of immunogenicity. Besides the size, many other factors can influence drugs’ 
immunogenicity, including variables related to the recipient (demographic charac-
teristics, genetics, underlying disease, concomitant immunosuppressive drugs) or to 
the drug itself (impurities, posttranslational modifications, doses, route and intervals 
between two consecutive administrations) [11]. In modern times, manufacturing 
techniques for the production of moAbs have evolved in order to restrain the degree of 
unwanted immunogenicity. One example is the process of humanization of moAbs, 
aiming at the replacement of primitive mouse domains with human ones [12].
The class of TNF-i agents used for rheumatic diseases includes antibodies with 
different molecular structures. Three of them (IFX, ADA and golimumab) are full-
length moAbs belonging to the human isotype class IgG1. IFX is a chimerical anti-
body, retaining 25% of the original murine structure, while ADA and golimumab 
are fully human moAbs. Etanercept (ETA) is a fusion protein consisting of two 
identical tumor necrosis factor receptor-2 (TNFR2) regions linked to the fragment 
crystallizable (Fc) of a human IgG1. Finally, certolizumab-pegol is a monovalent 
Fab fragment of a humanized anti-TNFα antibody conjugated to two molecules of 
polyethylene glycol (PEG) [13]. Though each of them works by neutralizing the 
pro-inflammatory cytokine TNF-α, differences in their molecular structures likely 
account for separate mechanisms of action and immunogenicity rates. Chimerical 
and human full-length moAbs are able to bind either soluble or transmembrane 
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TNF-α in a more efficient way than other TNF-i, eliciting complement-dependent 
cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and 
reverse signaling effects, including apoptosis, in transmembran TNFα-bearing cells 
[14]. In addition, TNF-i agents having the Fc can mediate other biological effects 
in FcγR-bearing cells like monocyte–macrophages, which may result either in the 
potentiation of immunetolerance or in the release of pro-inflammatory cytokines. 
This dual effect likely depends on the interaction of the drugs with different types 
of FcR, which may intracellularly transduce an inhibitory or activating signal.
This premise on the molecular characteristics and mechanisms of action of the 
licensed TNF-i is essential for clarifying many aspects related to the immunogenic-
ity of these drugs. Immunogenicity rates, in terms of anti-drug antibody (ADAb) 
formation, are in fact highly variable among patients undergoing TNF-i therapy 
[15]. Studies reported higher ADAb titers in rheumatoid arthritis (RA) patients 
treated with ADA and IFX and lower ADAb titers in patients treated with ETA, 
certolizumab pegol and golimumab [16]. The production of ADAbs in IFX-treated 
patients may be attributed to the chimerical structure of the drug. Similarly, ADAbs 
synthesized in ADA-treated individuals may recognize murine epitopes located 
in the complementarity-determining regions of ADA combinatory sites [17]. 
Moreover, full-length moAbs, like IFX and ADA, may be captured by dendritic cells 
by means of a Fc-dependent phagocytosis and antigenic fragments of the drugs may 
be presented to T helper (Th)2 lymphocytes, with the following stimulation of a 
humoral immune response leading to ADAb production [12]. The latter mechanism 
could be particularly pronounced in rheumatic patients having a constitutional 
hyper-activation of the B cell compartment, like those suffering from RA.
Serum ADAbs can be measured by means of several assays that display some 
sensitivity and specificity limits. They include the enzyme-linked immunosorbent 
assay (ELISA) and the electrochemiluminescence (ECL) assay, both based on bridg-
ing formats, the radioimmunoassay (RIA) and other antigen-binding tests (ABT) 
[15]. ELISA and ECL may underestimate the presence of monovalent ADAs, like 
those having an IgG4 isotype, while ABT seem to have higher sensitivity.
ADAb titers can widely vary according to sampling time and antibodies may 
belong to distinct isotype classes, have different affinity for the ligand or a variable 
degree of ligand neutralization [15]. ADAb belonging to the IgM, IgG, IgA and IgE 
isotypes have been reported in patients undergoing TNFi treatments [18, 19]. These 
antibodies can already be detected in the serum of IFX-treated patients between the 
second and the third infusion, whereas they may appear after 6 months of treatment 
in patients assuming ETA or ADA. Crucial is also the identification of neutralizing and 
non-neutralizing antibodies. The first may have a noteworthy impact on the efficacy 
of TNF-i treatment, whilst the second can play a major role in immunogenicity and 
immunogenicity-related adverse events, such as anaphylaxis, infusion reactions or 
cross-reactivity phenomena to endogenous proteins [11].
Recently, the introduction of drug-tolerant assays has allowed the possibility to 
detect immunocomplexes of ADAbs bound to TNF-i drugs, providing very relevant 
information in selected cases. The formation of immunocomplexes may in fact be 
at basis, on the one hand, of the development of a therapeutic non-response due 
to a higher clearance of opsonized drug by the reticuloendothelial system, while, 
on the other hand, it may explain the occurrence of some safety issues, like serum 
sickness-like reactions [20].
Post-translational modifications can have an additional impact on the biological 
effects of MoAbs and further influence their immunogenicity. For instance, a reduc-
tion in the content of fucose and an increase in the content of galactose and sialic acid 
of moAbs have shown to potentiate ADCC and CDC, indirectly favoring the clearance 
of the drug and its phagocytosis by antigen presenting cells (APC) [21].
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Finally, immunogenicity may occur as the hyper-activation of immunological 
axes other than the humoral branch. Our previous studies showed that RA patients 
experiencing a reduced efficacy or adverse events during the treatment with IFX 
may have an aberrant expansion of Th1, Th17 and Th9 lymphocytes to the detri-
ment of T regulatory subsets following the in vitro exposure to the drug [22, 23]. 
However, other authors showed that IFX may also favor the differentiation of IL-10-
producing T cells having an immunoregulatory phenotype [24].
Immunogenicity is a matter of crucial importance when it comes to biosimilars. 
Biosimilars may in fact differ from originators in terms of structural characteriza-
tion, glycan profile and purity/impurity content, which may altogether contribute 
to slight changes in the mechanism of action (neutralization of transmembrane of 
soluble TNFα, CDC or ADCC) compared to the originator counterparts [25, 26]. 
Despite the homology in the primary amino acid sequence, biosimilars may display 
substantial differences in the secondary (α-helices and β-strands), ternary (disul-
fide bonds) and quaternary (subunit arrangement and folding) structure as well as 
in post-translational modifications (glycosylation, oxidation, deamidation, meth-
ylation, acetylation, truncated isoforms) [25]. Intentional or unintentional changes 
to the original molecular structure may take place as a consequence of different 
manufacturing techniques, cell lines, culture media, purification, ultrafiltration or 
diafiltration processes.
Several divergences from reference products (RF) have been reported among 
the class of TNF-i biosimilars. The biosimilar IFX CT-P13 was shown to differ 
from its originator in terms of charged isoforms and carbohydrate chains, in turn 
associated with slight differences in the content rate of C-terminal lysine [27, 28]. 
Furthermore, it was reported an increased amount of fucosylated glycans in CT-P13 
compared to the RF [29]. Fucosylation seems to predominantly occur in the Fc 
domain of CT-P13 and to significantly impair the binding of FcγIIIa receptors on 
monocyte–macrophage cells, thus influencing ADCC and, possibly, immunogenic-
ity by preventing the internalization of the drug into APC [30, 23].
Similarly, the biosimilar ETA SB84 also showed slight differences in the amount 
of acidic variants, afucosylated and neutral galactosylated glycan content and 
O-glycan occupancy compared to the RF, despite no effects on its biological activ-
ity were reported in vitro. Interestingly, a lower particle concentration, aggregate 
content and product-related impurities were observed in SB4, which may account 
for reduced immunogenicity rates [31]. In another comparative exercise study, the in 
vitro characterization of the ETA biosimilar GP2015 did not evidence any significant 
differences with the originator according to the binding affinities to TNF-α, C1q and 
FcR [32]. When compared to its originator, the ADA biosimilar SB5 was reported to 
have a slightly higher content in free sulfhydryl groups and acidic variants that were 
however judged not clinically meaningful. The latter feature likely depends on lysine 
C-terminus content and degree of sialyation, although they were not associated with 
changes in SB5 biological activities [33]. Another study aiming to assess the physico-
chemical properties of the ADA biosimilar HLX03 reported a slightly lower percent-
age of high mannosylated glycans in the biosimilar drug, although this did not result 
in impaired FcγRIII binding and ADCC in human peripheral blood mononuclear 
cells [34].
In line with these preclinical considerations, results from clinical trials or regis-
try data collection reported similar immunogenicity rates with the use of biosimilar 
and branded TNF-i so that current guidelines and regulatory agencies recommend 
the use of biosimilars as an effective and safe alternative to originators [5].
The immunogenicity rates between branded and biosimilar IFX emerged from 
the two randomized controlled trials (RCTs) PLANETRA and PLANETAS enroll-
ing RA and ankylosing spondylitis (AS) patients and from the NOR-SWITCH and 
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DANBIO registries collecting the data of 482 patients with inflammatory bowel 
diseases (IBD), psoriasis (PsO) and psoriatic arthritis (PsA) and 802 patients with 
RA, spondyloarthritis (SpA) and PsA, respectively, appear similar [35]. Patients 
who were switched from originator to biosimilar IFX did not experience variations 
in ADAb serum concentration compared to patients who were not switched.
Similar results were obtained with ADA biosimilars. Pharmacokinetics studies 
conducted on healthy volunteers showed that the production of ADAbs, measured 
through ECL, may occur in up to 70% subjects following a single injection of ADA, 
being associated with a high proportion of neutralizing antibodies [36]. Although 
higher ADAb activity was associated with lower serum concentrations of ADA, 
the proportion of patients developing ADAbs was similar among biosimilar and 
originator treatment arms and ADAbs appeared cross-reacting. These data are 
in line with those of an ex-vivo study analyzing the sera of RA and IBD patients, 
which showed the presence of shared immune-dominant epitopes between biosimi-
lar and branded ADA [37]. Taken together, these results may also explain the lack 
of meaningful differences in ADAb titers in patients switched from originator to 
biosimilar ADA [38]. Phase III RCTs on the use of biosimilar ADA in patients with 
autoimmune diseases indicate similar or lower percentages of total and neutral-
izing ADAbs, being consistent between the experimental and the traditional arm of 
treatment. ADAb production has been however associated with a faster elimination 
of ADA and lower changes in disease activity scores from baseline [39–41].
RCTs conducted on RA and PsO patients treated with ETA biosimilar have 
shown a reduced percentage of ADAb production in the experimental arm with no 
detection of neutralizing antibodies [42, 43] Following the switch from reference 
ETA to its biosimilar no immunogenicity issue was observed in another RCT on RA 
patients after 24 weeks [44].
Based on these data and in consideration of the pharmacoeconomic advantages 
derived from the use of biosimilar rather than branded drugs, it would be natural 
to incentive the use of biosimilars not only as the first prescription but also as part 
of a switching strategy. Reassuring efficacy and safety data have in fact emerged 
from RCTs [39–47], which also reported non-significant variations in ADAb titers 
following the switch.
Nevertheless, lack of efficacy and reduced retention rates have been observed 
among rheumatic patients switched from originator to biosimilar TNF-i drugs 
in real-life. Data from registries on ETA- and IFX-treated RA, PsA and axial SpA 
patients followed-up for up to one year indicate a lower retention rate in switcher 
patients compared to historic cohorts, which seems mostly dependent on patients’ 
characteristics, including the underlying rheumatic disease and the disease activity 
at the time of the switch [48–50]. Since immunogenicity studies are usually not car-
ried out as a part of clinical and laboratory routine, it is unfair whether these results 
might mirror a real immunogenicity issue or rather represent a nocebo effect [51].
3. Biosimilars in real life
3.1 Etanercept
ETA is a fully soluble human dimeric fusion protein, which competes with 
soluble human TNF- α for binding cell-surfaced TNF receptors, precluding the 
activation of the inflammatory cascade. It is the only fusion receptor TNF-i avail-
able, as it differs from other biologics directed against TNF-α which are monoclonal 
antibodies. This difference may explain its minimal to none efficacy in granuloma-
tous diseases, including inflammatory bowel diseases. uveitis, and ANCA-related 
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vasculitis; on the other hand, ETA showed a better retention rate and a lower impact 
on the reactivation risk of tuberculosis infection [52].
ETA was the first TNFi approved in the United States (US) and Europe.
In1998 and in2000 respectively, ETA was approved by FDA (Food and Drug 
Administration) and EMA for the treatment of RA; shortly after this authorization, 
new indications were approved, including polyarticular juvenile idiopathic arthritis 
(JIA), PsA, AS, PsO and pediatric-PsO.
To date, three biosimilars of the originator ETA (Enbrel®)are available. On 
January 2016, SB4 (known as Benepali® in Europe) received the authorization 
from EMA for the same indications of its originator, whist FDA approved its use 
in the US on April 2019 (Eticovo®). GP2015(Erelzi®)was approved by EMA on 
June 2017 whileYLB113- (Nepexto®) on May 2020. All of these biologics have 
demonstrated the bioequivalence with the RF in clinical trials [42, 53–56] for at 
least one of the approved indications given to the originator and, based on the same 
mechanism of action, indications have been extrapolated for all approved indica-
tions (Table 1) [57]. Other biosimilars of ETA, approved neither by EMA nor by 
FDA, are available in the rest of the world [58].
Due to disputes about these extrapolations and the unrequested need to confirm 
the safety and efficacy of biosimilars in real life in rheumatic diseases, numerous 
real-life studies have been published in the last years. The vast majority of real-life 
data are focused on SB4, while more data derive from registries. One of the first 
established registries to compare SB4 with reference ETA was the nationwide 
observational Denmark DANBIO registry that included patients treated with ETA 
originator (2061) switched to SB4 (1621–79%) affected by RA, AxSpA and PsA 
(77%, 77% and 86%, respectively). The switched patients had a low disease activity 
and stable disease during the 3 months before the switch and received DMARDs 
less frequently than non-switchers. After one year of observation, authors found 
a lower retention-rate in SB4 population compared with the retention rate of a 
historic ETA originator cohort. They also found a higher withdrawal rate among 
non-switchers - 32.9% (145/440) - vs. switchers 18.4% (299/1621); however, disease 
activity was found to be higher in this group. During the follow-up, among the 299 
withdrew switchers to SB4, 120 patients needed to be switched back to the origina-
tor due to lack of efficacy. A sub-analysis of this group showed that the main reason 
SB4 failed was attributable to the patient perception of the disease (PGS - patient 
global score) rather than CRP or tender/swollen joints. The authors concluded 
that reasons to withdraw treatment were more frequently related with patients’ 
Indications IFX ETA ADA
Rheumatoid Arthritis √ √ √
Juvenile idiopathic arthritis — √ √
Psoriatic arthritis √ √ √
Ankylosing Spondylitis √ √ √
Crohn’s disease √ — √
Ulcerative colitis √ — √
Plaque psoriasis √ √ √
Pediatric Crohn’s disease √ — —





factors, such as being in remission or not and with subjective perception rather than 
objective evidence of poor disease activity control. No major adverse events were 
observed after the switch [48].
To date, data on SB4 from spontaneous studies are available.
A review published in 2019 focused on real world evidence about SB4, iden-
tifying 13,552 patients that used this biosimilar in Europe; among these patients, 
11,053 switched from the reference ETA while 768 (6.9%) switched back to the 
originator. The majority of patients included were affected by RA, PsA and SpA; 
there were also a small percentage of psoriatic patients without arthritis (2.5%) 
and a negligible proportion of patient affected by other inflammatory related 
diseases (Juvenile Arthritis and IBD, 0.1%). Outcomes included the effective-
ness of SB4 evaluated with a comparison between pre-switch and post-switch 
disease activity, retention rates, reasons for discontinuations, the evaluation of 
back-switchers, acceptance of the switch. In general, the results of this extensive 
review confirmed the efficacy of SB4 without statistically significant changes 
in laboratory or clinical parameters of inflammation and disease activity. No 
meaningful differences in the number of adverse events were observed before and 
after the switch, confirming its safety. However, a proportion of patients ranging 
between 3 to and 7.5 % switched back to the RF. Data about small studies showed 
that disease flares documented by ultrasound, CRP values or clinical examina-
tion represent the main reasons to switch. On the other hand, data about from 
DANBIO registry highlight the subjective factors (such as tender but not swollen 
joint count with, no differences in CRP serum levels) as the main reason to be 
switched back to the RF. The percentage of switching back was comparable to the 
smaller studies (7%). Retention rates of the included studies were at least 75% 
at 12 months of follow-up. By comparing results of two large registries (Spanish 
BIO-SPAN [59] and Danish DANBIO [48] authors found that the obligatory 
nature of the switch was not necessarily related with a higher acceptance rate; 
Spanish, Danish and Swedish [60] registries shared a higher concomitant use of 
methotrexate in the switchers. Other variables, such as the duration of usage of 
the originator and disease activity at the time of the switch were variably related 
with the degree of acceptance. A proper communication with the patient seemed 
to improve the acceptance rate of the switch as some authors found out that the 
older the patient or the longer the disease duration, the less accepted was the 
switch. Globally, acceptance rates ranged between 51.6% and 99.0%.The RABBIT 
registry confirmed the data of the registration study reporting lower rates of 
site reaction in patients treated with SB4 vs. the originator [61]. Differences in 
treatment practices, lack of clinician confidence with the drug andnocebo effects 
could have influenced this report [62].
More recently, two independent Italian groups published results from their SB4 
switch cohort from originator.
Both studies included patients affected by RA, PsA and AxSpA, treated with 
ETA originator who switched to ETA SB4.
The former is a single center studyincluding 80 patients in low disease activity. 
The aim was to evaluate the disease activity trend after the switch, comparing the 
trend during the 12 months before the switch with the trend at 12 months after 
switchthrough the analysis of disease activity parameters currently used for each 
diagnosis. Data analysis did not show significant differences in any of evaluated 
parameters after the switch from originator to biosimilar. A percentage of 12.6% 
(11 out of 85 patients) interrupted the treatment with the biosimilar due to lack 
of efficacy (7/11) or subjective features (2/11) or adverse events (2/11) which have 
been classified as not serious [63]. No correlation with demographic data, concomi-
tant therapy or disease duration was found.
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The second study included 220 patients in stable clinical conditions, from 2 
Italian University Hospital, in treatment with originator for at least 6 months; 
the period of observation was at least 6 months. Among them, 165 patients were 
observed up to 12 months while 65 patients were observed up to 18 months. 
Treatment persistence was observed to be 99.1%, 88.6% and 64.6% at 6, 12 and 
18 months, respectively. The interruption was due to lack of efficacy in the majority 
of cases (19 patients), whileit was discontinued due to safety issues in 11 patients. 
No interactions with other demographic or disease factors were found in this study 
as well [64].
In the overall data available about back-switching, the main reason was lack of 
efficacy, strictly followed by adverse events. However, the former was reported to 
be subjective by many authors.
3.2 Infliximab
IFX is a chimeric human-murine IgG1 monoclonal antibody produced in murine 
hybridoma cells by using recombinant DNA technology; it is approved for RA, 
AS, PsA, Crohn Disease (CD), Crohn Disease (CD), Ulcerative Colitis (UC) and 
PsO [65].
The originator product, Johnson & Johnson and Merck’s Remicade (IFX), was 
approved by the FDA in August 1998 and by the EMA in August 1999 [66].
The patents of reference IFX expired in the US in September 2018 and in Europe 
in February 2015. Some of the IFX biosimilars are presented in Table 2.
The NOR-SWITCH extension trial aimed to assess efficacy, safety and immu-
nogenicity in patients who used IFX CT-P13 throughout the 78-week study period 
(maintenance group) versus patients who switched to IFX CT-P13 at week 52 
(switch group).
Three hundred and eighty patients were recruited (197 in the maintenance 
group with the RF and 183 in the switch group). In the full analysis set, 127 (33%) 
had CD, 80 (21%) UC, 67 (18%) SpA, 55 (15%) RA, 20 (5%) PsA and 31 (8%) PsO. 
The primary outcome was disease worsening during follow-up based on disease-
specific evaluation parameters. The NOR-SWITCH extension showed no difference 
in safety and efficacy between patients who maintained CT-P13 and patients who 
switched from originator IFX to CT-P13, supporting the assertion that switching 
from originator IFX to CT-P13 is both safe and effective [69].
Other interesting data come from a French study published in 2018 by Avouac 
and coworkers [70], in which no change in objective disease activity measures nor 
in IFX levels were observed in 260 patients with chronic inflammatory diseases who 
were receiving maintenance therapy with innovator IFX and systematically shifted 
to biosimilar IFX CT-P13; 31 of them (11.9%) had RA and 131 (50.4%) had axSpA 
while the others had other inflammatory diseases (IBD above all). The retention 
rate was observed to be 85% (221 out of 260 patients) at the time of the third bio-
similar infusion. From the beginning of the switch to the last visit (mean follow-up 
of 34 weeks), 59 patients (23%) discontinued biosimilar IFX, mainly due to lack 
of efficacy (47, 80%). However, no clinical or biological factors were associated 
with biosimilar discontinuation. No serious adverse events occurred. No change 
in disease activity parameters or IFX levels was detected. However, a significant 
increase of BASDAI (2.94 ± 2.20 vs. 3.18 ± 2.21, P ¼ 0.046, before vs. after switch, 
respectively) was observed in patients with axSpA. Sensitivity analyses for effec-
tiveness included changes of disease activity parameters and IFX levels between 
baseline and the last visit as well as the occurrence of adverse events leading to drug 
discontinuation. No changes in IFX levels or objective parameters were observed 
after the systematic switch to biosimilar IFX in a real clinical practice setting. 
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Patient-reported outcomes were the only to be observed; a possible explaination 
could be, again, the nocebo effect rather than proper pharmacological differences, 
as demonstrated by the stability of objective measures (i.e. swollen joint count), 
CRP values and plasma levels of the drug.
Data from registries including DANBIO [49], also support the safety and 
efficacy of changing from a bio-originator to its biosimilar. The DANBIO registry 
evaluated 802 patients affected by RA, PsA and axial spondyloarthritis (AxSpA) 
who switched from originator IFX (IFX, Remicade) to biosimilar IFX CT-P13. The 
average follow-up was 413 (339–442) days. Disease activities 3 months before and 
after the switch as well as the changes over time were calculated. 1-year CT-P13 
retention rate was similar to the historic IFX cohort (84.1 vs. 86.2) and did not differ 
Company name Product name Stage of development
Amgen, USA Avsola (ABP 710) Approved by FDA in December 2019
Biocad, Russia BCD-055 Non-originator biologicalapproved in 
Russia in Feb 2018




Intravenous version approved in EU 
in September 2013. Subcoutaneous 
version approved in September 2019. 
Approved by FDA in April 2016.
Ixifi (PF-06438179) Pfizer received FDA approval for Ixifi 
in December 2017.




STI-002 Positive phase III trial for copy 




CMAB008 Copy biological submitted to China’s 
NMPA for approval in January 2020
Nichi-Iko Pharmaceutical, Japan NI-071 Phase III trial in rheumatoid 
arthritis expected to be completed 
in March 2015. Approved in Japan in 
September 2017. US phase III trial in 
rheumatoid arthritis expected to be 
completed February 2019.
NipponKayaku, Japan IFX BS Approved in Japan in November 2014
Ranbaxy Laboratories/Epirus 
Biopharmaceuticals, India*/USA
BOW015 ‘Similar biologic’ approved in India in 
December 2014. Global phase III trial 





Approved in EU in May 2016. 
Approved by FDA in April 2017.
Sandoz, Switzerland Zessly (PF-06438179) Sandoz acquired EEA rights from 




Baimaibo Phase III trial in RA in China started 
March 2018
EC: European Commission; EEA: European Economic Area, this area includes the 28 EU Member States, plus 
Iceland, Liechtenstein and Norway; EMA: European Medicines Agency; EU: European Union; FDA: US Food and 
Drug Administration; NMPA: National Medical Products Administration. Adapted by https://www.gabionline.net/
Biosimilars/General/Biosimilars-of-IFX [67, 68].
Table 2. 
Biosimilars and non-originator biologicals of IFX.
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significantly from the bio-originator. Results showed that 132 patients discontinued 
biosimilar IFX due to lack of effect (71/132 = 54%), followed by adverse events 
(37/132 = 28%). Authors found that patients with previous IFX treatment with a 
duration of >5 years had longer CT-P13 retention.
Smaller ‘real-world’ observational studies also confirmed comparable efficacy 
and safety of transitioning from originator to biosimilar IFX CT-P13 to that of 
continuing treatment with biooriginator IFX [71, 72].
In a single centre in Finland, Nikiphorou and colleagues observed similar 
patient-reported disease activity and symptoms after transitioning to biosimilar 
IFX CT-P13. Thirty-nine consecutive patients with RA (38%), AS (36%), PsA 
(18%), juvenile idiopathic arthritis (JIA) (5%), chronic reactive arthritis (3%), 
were switched to biosimilar after a mean (SD) of 4.1 (2.3) years on IFX. Thirty-one 
patients were on concomitant methotrexate.
At a median (range) of 11 (7.5–13) months following the first administration 
of IFX-biosimilar-CT-P13, disease activity and patient reported outcomes (PROs) 
were similar for IFX-originator and IFX-biosimilar-CT-P13. Eleven patients (28.2%) 
discontinued biosimilar-CT-P13, due to anti-IFX originator antibodies (n = 3), 
subjective reasons with no objective deterioration of disease (n = 6) or other causes 
(latent tuberculosis, n = 1, new-onset neurofibromatosis, n = 1); the clinical effec-
tiveness of IFX biosimilar in both PROs and disease-activity measures was compa-
rable to IFX originator during the first year of switching. Authors did postulate that 
subjective reasons (negative expectations) may play a role among discontinuations 
of biosimilars [73].
Similar results were obtained by German and colleagues [74], that aimed to 
assess the long-term retention rate of CT-P13 after switching from originator IFX, 
wich appeared to be identical to a historical cohort, confirming the safety, efficacy 
and acceptability of the switch in the long term (median follow-up of 120 weeks; 
range 6–145). Among the 39 withdrawals, 25 (64%) patients discontinued CT-P13 
during the first period of follow-up. Reasons for stopping CTP-13 belatedly 
included an objective clinical worsening in 5/14 patients, non-serious safety issues 
in 6/14 patients (psoriatic lesions, digestive disorders, asthenia and subjective 
neurological symptoms with negative extensiveinvestigations and stable remission 
in 3/14 patients). No case of subjective clinical worsening was observed during the 
second period of the follow-up. The weight of patients’ acceptance was also taken 
into account in a cohort of 89 patients (63 AS, 12 PsA and 14 RA) that agreed to 
switch from the originator to CTP-13 [75]. After a median follow-up of 33 weeks, 
72% of patients were still treated with CT-P13. This rate of maintenance was signifi-
cantly lower than the one found in the historical control cohorts and prospective 
study cohorts: 88% and 90% respectively (p = 0.0002). Among patients requesting 
a return to the originator, 13/25 (52%) showed clinical activity for their disease, one 
patient presented with serum sickness and 11 (44%) did not exhibit objective activ-
ity. An analysis excluding these 11 patients eliminated the difference in retention 
rate between the 3 cohorts (p = 0.453) suggesting patient reluctance to switch and 
negative perception of the biosimilar.
After returning to the originator, patients without objective clinical activity all 
returned to their previous state.
In a cohort of 222 patients treated with originator, 192 agreed to switch to 
CT-P13 as they were included in a Dutch multicenter prospective cohort study 
(BIO-SWITCH) [76]. Patients with a clinical diagnosis of either RA, PsA, or AS 
who agreed (transition group) or did not agree (control group) to transition to 
CT-P13 were both eligible for inclusion in the study. During 6 months follow-up, 
24% of the patients (n = 47) discontinued CT-P13. 37 patients restarted origina-
tor, 7 switched to another biologic drug, and 3 continued without a biologic drug. 
Biosimilars
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The DAS28-CRP remained stable from baseline to month 6. The BASDAI slightly 
increased (difference of +0.5 [95% CI 0.1, 0.9]); CRP, IFX levels and anti-IFX 
antibody levels did not change. Just before CT-P13 discontinuation, DAS28-CRP 
components tender joint count and patient’s global assessment of disease activity, 
as well as BASDAI, were increased when compared to baseline. The most fre-
quently reported AEs were arthralgia, fatigue, pruritus, and myalgia. One-fourth 
of patients discontinued CT-P13 during 6 months of follow-up, mainly due to an 
increase in the subjective features of the tender joints count and the patient’s global 
assessment of disease activity and/or subjective symptoms, possibly explained by 
nocebo effects and/or incorrect causal attribution effects.
Boone and colleagues [77], aimed to investigate the role of the nocebo effect in a 
cohort of 125 patients enrolled in the study (73 CD, 28 UC, 9 RA, 10 PsA and 5 AS). 
As expected they have shown no statistically significant changes in effectiveness 
and safety in any of the indications after a median of 4 infusions in 9 months but 
they hilighted the nocebo response of 12.8% was found among the patients during 
a minimal observation period of 6 months after the transition to biosimilar IFX 
without differences between the indications.
For SB2 the real-life data available are fewer and they are related to Inflammatory 
Bowel diseases and PSO [78]. In the work of Fautrel [78], only Four SAEs were 
reported: one considered related to SB2 (infected cyst) and three unrelated (two RA 
disease flares and one overdose of vitamin K antagonists).
There is less evidence regarding the cross-switch from different IFX 
biosimilars.
Gisondi et al. [79] investigated the effectiveness and safety of cross-switching 
from CT-P13 to SB2 in 24 patients with PsO and they concluded that it was not 
associated with a significant change in PASI score or additional adverse events.
Same result were obtained by Bazzani et al. [80]. The Authors retrospectively 
evaluated the efficacy and safety of the sequential use of 2 biosimilars of IFX in 50 
patients already being treated with Remicade® for AS (25 patients), RA (15 patients) 
and PSA (10 patients) ant they did not found significant alterations in the clinical 
response. The safety profile was also not modified by this therapeutic model.
3.3 Adalimumab
In 2002 Humira, the originator ADA, became the third TNFi to be approved in 
the USA after IFX and ETA. ADA has shown excellent efficacy and safety and it is 
widely used in clinical treatment for RA [81]. It is the best-selling drug worldwide, 
with global sales worth $18 billion in 2017 alone [82]. It is also one of the most ver-
satile drugs, seeing as it has been approved SpA, PSO, PsA, CD, UC, polyarticular 
juvenile idiopathic arthritis (JIA), hidradenitis suppurativa (HS) and noninfectious 
uveitis [83].
Currently, seven ADA biosimilars are approved either in the EU and/or the 
USA: ABP 501, BI 695501, FKB327, GP2017, MSB11022, PF-06410293 and SB5, 
all of which have been proven to be similar in terms of safety and efficacy to the 
licensed RF (RP). ADA is a recombinant, fully human, IgG1 monoclonal antibody 
that is structurally and functionally indistinguishable from naturally occurring 
human IgG1. It was engineered through phage display technology and it is produced 
in a Chinese hamster ovary cell line [84]. ADA is administered by subcutaneous 
injection and its peak plasma concentration is reached after approximately 131 h. 
It possesses a widely distribution which includes the synovium. Similar to natu-
rally occurring human IgG, its elimination half-life is roughly 10 to 14 days. ADA 
specifically binds to TNF-alpha (both soluble and membrane-bound) and blocks 
the interaction with p55 and p75 cell-surfaced TNF receptors [85]. Despite being a 
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fully human antibody, up to 30% of RA patients develop ADAb again ADA. ADA 
can prevent the drug from binding to its target and/or forming immune complexes; 
such phenomena decrease serum drug levels and increase markers of inflammation 
in RA patients [86]. Amgen’s ABP 501 was the first ADA biosimilar to be approved 
by FDA in 2016 (Amjevita®) and by EMA in 2017 (as Amgevita/Solymbic®). 
Boehringer Ingelheim’s BI 695501 (Cyltezo®) was approved by the EMA and FDA 
in 2017. Samsung Bioepis’s SB5 (Imraldi®) was approved by the EMA in 2017 and by 
the FDA in 2019. FKB327 (Hulio®) was approved by the EMA and FDA in 2018 and 
2020, respectively while GP2017 (Hyrimoz®/Hefya®/Halimatoz®) was approved 
by the FDA and EMA in 2018, finally MSB11022 (Hidacio®) was approved by the 
EMA in 2019. PF-06410293 (Abrilada®, Amsparity®) was approved by the FDA 
and EMA in 2019 and 2020, respectively.
Unlike biosimilar IFX and ETA [87] there are not many open label extension or 
pharmacovigilance studies for biosimilar ADA.
Despite a lot of data from registration studies, including single switch, multiple 
switch and switch-back strategies from RF, proving the safety and efficacy of 
ADA biosimilars, no data on real life switch from ADA-RF to ADA biosimilars are 
available.
4. Final considerations
Real-life data confirm both efficacy and safety of biosimilars based on large-
scale studies.
In clinical practice, the switch from the RF to a biosimilar must be based on 
a shared decision between the patient and the prescribing physician. It is worth 
noticing that if a biosimilar gets the “interchangeability” designation allowed by the 
FDA, it could be automatically substituted at the pharmacy level without consult-
ing the prescribing physician [88]. This designation can be applied only if the 
manufacturer is able to provide sufficient evidence that “the risk in terms of safety 
or diminished efficacy of alternating or switching between use of the biological 
product (biosimilar) and the RF is not greater than the risk of using the RF without 
such alternation or switch.” “To date none of the biosimilars have received such 
designation. Despite controversies regarding the non-medical switch, biosimilars 
are becoming substitutes of branded biological agents for their lower cost, for the 
reassuring data on adverse events and serious adverse events not only from registra-
tion studies but from real-life studies. Furthermore, biosimilars have the opportu-
nity to make biologic treatment for rheumatic diseases more widely available.
Regarding immunogenicity there are several possible factors that may confound 
the results. Firstly, concomitant medications might affect the incidence of ADAbs 
and nAbs. In the phase III trials of all biosimilars, patients used MTX while being 
treated with biologics, but the combination of MTX therapeutic protein-drug inter-
actions, which can then reduce the incidence of ADAbs and improve efficacy [89] . 
Secondly, most of the trials allowed patients to be treated with <2 biologic therapies 
prior to the start of the trial, which may have a potential impact on the incidence of 
ADAbs and nAbs. Moreover, the incidence of ADAbs and nAbs increased with the 
duration of treatment [90]. Based on the real-life analysis all of biosimilars showed 
comparable efficacy, safety, and immunogenicity to the RP. Subtle differences are 
considered to be present due to methodological bias rather than the properties of 
biosimilars.
The results of studies about the switch from RP to biosimilars, confirmed in 
most real-life reports, have shown that switching from RP to a biosimilar does not 
have a significant impact on efficacy, safety, and immunogenicity. Most of the data 
Biosimilars
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regarding the switch-back or the withdrawal treatment showed that the nocebo 
effect plays a not negligible role, even if objective disease flares can occur.
To conclude, biosimilars will offer exciting opportunities in improving treat-
ment access and increasing treatment options worldwide in the next years. They 
have the potential to cause an unprecedented impact on the utilization of biologic 
medications and will continue to challenge originator biologic therapies.
Similar to TNFi biosimilars already on the market, real-world data and phar-
macovigilance studies are critical to developing long-term evidence to provide 
assurances on efficacy as well as safety. These biosimilars will offer exciting oppor-
tunities in improving treatment access and increasing treatment options worldwide.
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